Abstract：To investigate the clinical distributions and antimicrobial susceptibility of Acinetobacter baumannii (A. baumannii) strains in Fujian from 2008 to 2012, 5 907 non-duplicate strains were isolated in the First Affiliated Hospital of Fujian Medical University. They were mainly from departments of ICU (34.5%), pneumologie (12.7%), neurology (22.1%), and orthopedics (8.3%). The sensitive results of strains from both disc diffusion and automatic microbiological system methods were acceptable according to CLSI standards. All data were analyzed by WHONET5.4 or SPSS 16.0. Results showed that the antibiotic resistance of A. baumannii was still increasing. Minocycline, amikacin and tigecycline have good antibacterial activity against A. baumannii, while the resistance rates to cefperazone-sulbactam and carbapenems rose gradually. The resistance rates to minocycline and amikacin were 1.9%-7.5% and 15.0%-38.0%, respectively. The susceptibility rates to tigecycline were 86.1%. During 2009 to 2011, the resistance rates to cefperazone-sulbactam fluctuated from 19.1% to 27.1%, but rose to 52.2% in 2012. The rates resistant to meropenem and imipenem also rose gradually to 72.7% and 63.4% during the 5 years. The percents of MDRAB were increasing from 14.2% to 46.5%. It meant the resistant trend to antibiotics was developing to multidrug resistance with the increasing numbers of A. baumannii isolated.
林宇岚,杨滨,陈守涛,高丽钦,陈曦,甘龙杰,欧启水. 2008-2012年福建省5 907株鲍曼不动杆菌临床分布及耐药性分析[J]. 中国人兽共患病学报, 2014, 30(4): 383-386.
LIN Yu-lan,YAN Bin,CHEN Shou-tao,GAO Li-qin,CHEN Xi,GAN Long-jie,OU Qi-shui. Clinical distribution and drug resistance of 5 907 Acinetobacter baumannii strains isolated during 2008 and 2012 in Fujian Province, China. Chinese Journal of Zoonoses, 2014, 30(4): 383-386.
[1] Choi WS, Kim SH, Jeon EG, et al. Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in Intensive Care Units and successful outbreak control program[J]. J Korean Med Sci, 2010, 25(7): 999-1004. DOI: 10.3346/jkms.2010.25.7.999 [2]Wang H, Ni YX, Chen MJ, et al. Performance standards for antimicrobial susceptibility testing of a novel glycylcycline: tigecycline[J]. Chin J Lab Med, 2009, 32(11):1208-1213. DOI: 10.3760/cma.j.issn.1009-9158.2009.11.002 (in Chinese) 王辉,倪语星,陈民钧,等.新型甘氨酰环素类抗菌药物替加环素的体外药敏试验操作规程[J].中华检验医学杂志,2009,32(11):1208-1213. [3]Xiao YH, Shen P, Wei ZQ, et al. Moharin report of 2011: monitoring of bacterial resistance in China[J]. Chin J Nosocomiol, 2012, 22(22): 4946-4952. (in Chinese) 肖永红,沈萍,魏泽庆,等. Mohnarin 2011年度全国细菌耐药监测[J].中华医院感染学杂志,2012,22(22):4946-4952. (in Chinese) [4]Hu FP, Zhu DM, Wang F, et al. 2011 CHINET surveillance of bacterial resistance in China[J]. Chin J Infect Chemother, 2012, 12(5): 321-329. (in Chinese) 胡付品,朱德妹,汪复,等. 2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. [5]Karageorgopolulus DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J]. Lancet Infect Dis, 2008, 8(12): 751-762. DOI: 10.1016/S1473-3099(08)70279-2 [6]Xi HM, Xu YC, Zhu DM, et al. Chinet 2010 surveillance of antibiotic resistance in Acinetobacter baumannii in China[J]. Chin J Infect Chemother, 2012, 12(2): 98-104. (in Chinese) 习慧明,徐英春,朱德妹,等.2010年中国CHINET鲍曼不动杆菌耐药性监测[J]. 中国感染与化疗杂志,2012,12(2):98-104. [7]He FM, Fan J, Yu ZB, et al. Analysis of clinical evaluation of Acinetobacter baumannii in the ICU sputum sample sources[J]. Chin J Antibiotics, 2012, 37(5): 357-361. (in Chinese) 何发明,范晶,余泽波,等.ICU中痰标本来源的鲍曼不动杆菌的临床意义分析[J].中国抗生素杂志,2012,37(5):357-361. [8]Chen BY, He LX, Hu BJ, et al. Diagnosis and therapy of Acinetobacter baumannii infections: the Same Minds of Experts in China[J]. Natl Med J China, 2012, 92(2): 76-85. DOI: 10.3760/cma.j.issn.0376-2491.2012.02.002 (in Chinese) 陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85. [9]Walsh TR, Toleman MA, Poirel L, et al. Metallo-lactamases: the quiet before the storm[J]. Clin Microbiol Rev, 2005, 18: 306-325. DOI: 10.1128/CMR.18.2.306-325.2005 [10]Limansky AS, MussiMA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance[J]. J Clin Microbiol, 2002, 40: 4776-4778. DOI: 10.1128/JCM.40.12.4776-4778.2002 [11]Ma XZ, LU L. Mechanisms of resistance to selected antibiotics in Acinetobacter baumannii[J]. Chin J Clin Pharmacol, 2009, 25(1): 90-94. DOI: 10.3969/j.issn.1001-6821.2009.01.023 (in Chinese) 马序竹,吕媛.鲍曼不动杆菌对主要抗菌药物耐药机制[J].中国临床药理学 杂志,2009,25(1):90-94. [12]Wang H, Guo P, Sun H, et a1. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals[J]. Antimicrob Agents Chemother, 2007,51(11): 4022-4028. DOI: 10.1128/AAC.01259-06 [13]Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tige-cycline gainstmultiple-drug- resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek Hospitals[J]. Antimicrob Agents Chemother, 2006, 50: 3166-3169. DOI: 10.1128/AAC.00322-06 [14]Zhang XJ, Xu YC,Yuan Y, et al.In vitro activity of tigecycline and other 13 antimicrobial agents against multi-drug resistant bacteria[J]. Chin J Infect Chemother, 2009, 9(5): 365-368. DOI: 10.3321/j.issn:1009-7708.2009.05.010 (in Chinese) 张小江,徐英春,原英,等.替加环素等14种抗菌药物对多重耐药菌的体外抗菌活性研究[J].中国感染与化疗杂志,2009,9(5):365-368. [15]Sun Q, Zhou HW, Hu YY, et al. The resistance of multi-drug resistant Acinetobacter baumannii to tigecycline[J]. Chin J Lab Med, 2011, 34(4): 358-361. DOI: 10.3760/cma.j.issn.1009-9158.2011.04.015 (in Chinese) 孙谦,周宏伟,胡燕燕,等.多重耐药鲍曼不动杆菌对替加环素耐药状况分析[J].中华检验医学杂志,2011,34(4):358-361.
2014, Vol. 30 
